xRead - September 2022

Wise et al.

Page 404

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Study Year LOE Study design Study groups Clinical endpoint Conclusion Ratner et al. 1494 2008 1b DBRCT 1 AzeFlu; 2 Azelastine; 3 Fluticasone propionate Total symptom score

TNSS Combination superior to either agent alone.

Berger et al. 1495 2016 2b RCT, non-blinded 1 AzeFlu; 2 Fluticasone propionate observational observational AzeFlu VAS Rapid symptom relief across all age groups. AzeFlu = combination spray of azelastine hydrochloride and fluticasone propionate; DBRCT = double-blind randomized controlled trial; LOE = level of evidence; PRQLQ = Pediatric Rhinoconjunctivitis Quality of Life Questionnaire; QOL = quality of life; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; rTNSS = reflective Total Nasal Symptom Score; rTOSS = reflective Total Ocular Symptom Score; TNSS = Total Nasal Symptom Score; VAS = visual analog AzeFlu superior to fluticasone for children; faster onset. Klimek et al. 1496 2016 2c Prospective AzeFlu VAS 76% of subjects had symptom control after 14 days; significant improvement from baseline. Klimek et al. 1497 2015 2c Prospective

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.